OBJECTIVE: To propose a novel measure, namely the 'asphericity' (ASP), of spatial irregularity of FDG uptake in the primary tumour as a prognostic marker in head-and-neck cancer. METHODS: PET/CT was performed in 52 patients (first presentation, n = 36; recurrence, n = 16). The primary tumour was segmented based on thresholding at the volume-reproducible intensity threshold after subtraction of the local background. ASP was used to characterise the deviation of the tumour's shape from sphere symmetry. Tumour stage, tumour localisation, lymph node metastases, distant metastases, SUVmax, SUVmean, metabolic tumour volume (MTV) and total lesion glycolysis (TLG) were also considered. The association of overall (OAS) and progression-free survival (PFS) with these parameters was analysed. RESULTS: Cox regression revealed high SUVmax [hazard ratio (HR) = 4.4/7.4], MTV (HR = 4.6/5.7), TLG (HR = 4.8/8.9) and ASP (HR = 7.8/7.4) as significant predictors with respect to PFS/OAS in case of first tumour manifestation. The combination of high MTV and ASP showed very high HRs of 22.7 for PFS and 13.2 for OAS. In case of recurrence, MTV (HR = 3.7) and the combination of MTV/ASP (HR = 4.2) were significant predictors of PFS. CONCLUSIONS: ASP of pretherapeutic FDG uptake in the primary tumour improves the prediction of tumour progression in head-and-neck cancer at first tumour presentation. KEY POINTS: Asphericity (ASP) characterises the spatial heterogeneity of FDG uptake in tumours. ASP is a promising prognostic parameter in head-and-neck cancer. ASP is useful for identification of high-risk patients with head-and-neck cancer.
OBJECTIVE: To propose a novel measure, namely the 'asphericity' (ASP), of spatial irregularity of FDG uptake in the primary tumour as a prognostic marker in head-and-neck cancer. METHODS: PET/CT was performed in 52 patients (first presentation, n = 36; recurrence, n = 16). The primary tumour was segmented based on thresholding at the volume-reproducible intensity threshold after subtraction of the local background. ASP was used to characterise the deviation of the tumour's shape from sphere symmetry. Tumour stage, tumour localisation, lymph node metastases, distant metastases, SUVmax, SUVmean, metabolic tumour volume (MTV) and total lesion glycolysis (TLG) were also considered. The association of overall (OAS) and progression-free survival (PFS) with these parameters was analysed. RESULTS: Cox regression revealed high SUVmax [hazard ratio (HR) = 4.4/7.4], MTV (HR = 4.6/5.7), TLG (HR = 4.8/8.9) and ASP (HR = 7.8/7.4) as significant predictors with respect to PFS/OAS in case of first tumour manifestation. The combination of high MTV and ASP showed very high HRs of 22.7 for PFS and 13.2 for OAS. In case of recurrence, MTV (HR = 3.7) and the combination of MTV/ASP (HR = 4.2) were significant predictors of PFS. CONCLUSIONS:ASP of pretherapeutic FDG uptake in the primary tumour improves the prediction of tumour progression in head-and-neck cancer at first tumour presentation. KEY POINTS: Asphericity (ASP) characterises the spatial heterogeneity of FDG uptake in tumours. ASP is a promising prognostic parameter in head-and-neck cancer. ASP is useful for identification of high-risk patients with head-and-neck cancer.
Authors: Joost L Knegjens; Michael Hauptmann; Frank A Pameijer; Alfons J Balm; Frank J Hoebers; Josien A de Bois; Johannes H Kaanders; Carla M van Herpen; Cornelia G Verhoef; Oda B Wijers; Ruud G Wiggenraad; Jan Buter; Coen R Rasch Journal: Head Neck Date: 2011-03 Impact factor: 3.147
Authors: Remy Lim; Anne Eaton; Nancy Y Lee; Jeremy Setton; Nisha Ohri; Shyam Rao; Richard Wong; Matthew Fury; Heiko Schöder Journal: J Nucl Med Date: 2012-08-14 Impact factor: 10.057
Authors: F Hofheinz; C Pötzsch; L Oehme; B Beuthien-Baumann; J Steinbach; J Kotzerke; J van den Hoff Journal: Nuklearmedizin Date: 2011-10-26 Impact factor: 1.379
Authors: Elizabeth H Dibble; Ana C Lara Alvarez; Minh-Tam Truong; Gustavo Mercier; Earl F Cook; Rathan M Subramaniam Journal: J Nucl Med Date: 2012-04-09 Impact factor: 10.057
Authors: Trang H La; Edith J Filion; Brit B Turnbull; Jackie N Chu; Percy Lee; Khoa Nguyen; Peter Maxim; Andy Quon; Edward E Graves; Billy W Loo; Quynh-Thu Le Journal: Int J Radiat Oncol Biol Phys Date: 2009-03-14 Impact factor: 7.038
Authors: Mark J Been; Joanna Watkins; Ryan M Manz; Lindell R Gentry; Glen E Leverson; Paul M Harari; Gregory K Hartig Journal: Laryngoscope Date: 2008-08 Impact factor: 3.325
Authors: Dominic A X Schinagl; Paul N Span; Wim J Oyen; Johannes H A M Kaanders Journal: Eur J Nucl Med Mol Imaging Date: 2011-04-02 Impact factor: 9.236
Authors: Joël Castelli; A Depeursinge; A Devillers; B Campillo-Gimenez; Y Dicente; J O Prior; E Chajon; F Jegoux; C Sire; O Acosta; E Gherga; X Sun; B De Bari; J Bourhis; R de Crevoisier Journal: Eur J Nucl Med Mol Imaging Date: 2018-08-21 Impact factor: 9.236
Authors: Christoph Wetz; I Apostolova; I G Steffen; F Hofheinz; C Furth; D Kupitz; J Ruf; M Venerito; S Klose; Holger Amthauer Journal: Mol Imaging Biol Date: 2017-06 Impact factor: 3.488
Authors: Gianpiero Manca; Eleonora Vanzi; Domenico Rubello; Francesco Giammarile; Gaia Grassetto; Ka Kit Wong; Alan C Perkins; Patrick M Colletti; Duccio Volterrani Journal: Eur J Nucl Med Mol Imaging Date: 2016-01-19 Impact factor: 9.236
Authors: Michael R Folkert; Jeremy Setton; Aditya P Apte; Milan Grkovski; Robert J Young; Heiko Schöder; Wade L Thorstad; Nancy Y Lee; Joseph O Deasy; Jung Hun Oh Journal: Phys Med Biol Date: 2017-06-12 Impact factor: 3.609